National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Res

[1]  L. Harrison,et al.  Dynamics of antimicrobial resistance of Streptococcus pneumoniae following PCV10 introduction in Brazil: Nationwide surveillance from 2007 to 2019. , 2021, Vaccine.

[2]  S. de Lusignan,et al.  Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial , 2021, The Lancet.

[3]  Venugopal Arumuru,et al.  Experimental visualization of sneezing and efficacy of face masks and shields , 2020, Physics of fluids.

[4]  T. Lauderdale,et al.  Serotype Distribution and Antimicrobial Susceptibility of Streptococcus pneumoniae in Pre- and Post- PCV7/13 Eras, Taiwan, 2002–2018 , 2020, Frontiers in Microbiology.

[5]  E. Burhan,et al.  Serotype distribution and antimicrobial profile of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Jakarta, Indonesia. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[6]  P. Hsueh,et al.  Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? , 2020, Journal of Microbiology, Immunology and Infection.

[7]  C. Chiu,et al.  Divergent serotype distribution between children with otitis media and those without in the pneumococcal conjugate vaccine era. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[8]  Wen-Sen Lee,et al.  In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[9]  Stefan Ma,et al.  Decreased Influenza Incidence under COVID-19 Control Measures, Singapore , 2020, Emerging infectious diseases.

[10]  Yu-Chia Hsieh,et al.  Genomic Insight into the Spread of Meropenem-Resistant Streptococcus pneumoniae Spain23F-ST81, Taiwan , 2020, Emerging infectious diseases.

[11]  B. Cowling,et al.  Respiratory virus shedding in exhaled breath and efficacy of face masks , 2020, Nature Medicine.

[12]  M. Huband,et al.  Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018 , 2020, Antimicrobial Agents and Chemotherapy.

[13]  Yhu-Chering Huang,et al.  The antimicrobial susceptibility in adult invasive pneumococcal disease in the era of pneumococcus vaccination: A hospital-based observational study in Taiwan. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[14]  C. Chiu,et al.  Non-typeable Streptococcus pneumoniae infection in a medical center in Taiwan after wide use of pneumococcal conjugate vaccine. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[15]  K. Kuo,et al.  The clinical implication of serotype distribution and drug resistance of invasive pneumococcal disease in children: A single center study in southern Taiwan during 2010-2016. , 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[16]  Chin-Fu Lin,et al.  Respiratory pathogens - Some altered antibiotic susceptibility after implementation of pneumococcus vaccine and antibiotic control strategies. , 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[17]  C. Chiu,et al.  Successful Control of Streptococcus pneumoniae 19A Replacement With a Catch-up Primary Vaccination Program in Taiwan. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  K. Thomas,et al.  Invasive pneumococcal disease in Indian adults: 11 years' experience. , 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[19]  N. Andrews,et al.  Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018. , 2019, Vaccine.

[20]  N. Andrews,et al.  Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. , 2018, The Lancet. Infectious diseases.

[21]  H. Lee,et al.  Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis , 2018, PloS one.

[22]  R. Malley,et al.  Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies , 2015, Clinical and Vaccine Immunology.

[23]  H. Schmitt,et al.  Pneumococcal serotype evolution in Western Europe , 2015, BMC Infectious Diseases.

[24]  V. Nizet,et al.  Examining the Use of Ceftaroline in the Treatment of Streptococcus pneumoniae Meningitis with Reference to Human Cathelicidin LL-37 , 2015, Antimicrobial Agents and Chemotherapy.

[25]  N. Andrews,et al.  Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. , 2014, The Lancet. Infectious diseases.

[26]  Meng-Rui Lee,et al.  Capsular serotypes and antimicrobial susceptibilities of Streptococcus pneumoniae causing invasive pneumococcal disease from 2009-2012 with an emphasis on serotype 19A in bacteraemic pneumonia and empyema and β-lactam resistance. , 2013, International journal of antimicrobial agents.

[27]  W. Ko,et al.  Trends in the antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. , 2013, International journal of antimicrobial agents.

[28]  W. Schaffner,et al.  Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  P. Hsueh,et al.  Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  L. Hammitt,et al.  Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. , 2006, The Journal of infectious diseases.

[31]  R. de Groot,et al.  Streptococcus pneumoniae colonisation: the key to pneumococcal disease. , 2004, The Lancet. Infectious diseases.

[32]  J. Wu,et al.  Telithromycin- and Fluoroquinolone-Resistant Streptococcus pneumoniae in Taiwan with High Prevalence of Resistance to Macrolides and β-Lactams: SMART Program 2001 Data , 2003, Antimicrobial Agents and Chemotherapy.

[33]  Clinical,et al.  Performance standards for antimicrobial susceptibility testing , 2019 .

[34]  W. Schaffner,et al.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.

[35]  D. Rolo,et al.  Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.